- Home
- QIPT vs GLSI Comparison
QIPT vs GLSI Comparison
Compare QIPT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- GLSI
- Stock Information
- Founded
- QIPT 1993
- GLSI 2006
- Country
- QIPT United States
- GLSI United States
- Employees
- QIPT N/A
- GLSI N/A
- Industry
- QIPT
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- GLSI Health Care
- Exchange
- QIPT Nasdaq
- GLSI Nasdaq
- Market Cap
- QIPT 104.7M
- GLSI 108.8M
- IPO Year
- QIPT N/A
- GLSI 2020
- Fundamental
- Price
- QIPT $2.41
- GLSI $8.42
- Analyst Decision
- QIPT Buy
- GLSI Strong Buy
- Analyst Count
- QIPT 2
- GLSI 1
- Target Price
- QIPT $3.15
- GLSI $39.00
- AVG Volume (30 Days)
- QIPT 278.0K
- GLSI 84.7K
- Earning Date
- QIPT 12-15-2025
- GLSI 11-14-2025
- Dividend Yield
- QIPT N/A
- GLSI N/A
- EPS Growth
- QIPT N/A
- GLSI N/A
- EPS
- QIPT N/A
- GLSI N/A
- Revenue
- QIPT $238,378,000.00
- GLSI N/A
- Revenue This Year
- QIPT N/A
- GLSI N/A
- Revenue Next Year
- QIPT $28.69
- GLSI N/A
- P/E Ratio
- QIPT N/A
- GLSI N/A
- Revenue Growth
- QIPT N/A
- GLSI N/A
- 52 Week Low
- QIPT $1.35
- GLSI $7.78
- 52 Week High
- QIPT $3.27
- GLSI $15.47
- Technical
- Relative Strength Index (RSI)
- QIPT 52.68
- GLSI 43.03
- Support Level
- QIPT $2.15
- GLSI $7.78
- Resistance Level
- QIPT $2.39
- GLSI $8.53
- Average True Range (ATR)
- QIPT 0.11
- GLSI 0.51
- MACD
- QIPT 0.01
- GLSI 0.08
- Stochastic Oscillator
- QIPT 76.12
- GLSI 43.02
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.